• Return to Headlines

Relatively Low EBITDA Growth Detected in Shares of United Therapeut in the Biotechnology Industry (UTHR, GILD, AMAG, AMGN, EBS)

By Nick Russo

Below are the three companies in the Biotechnology industry with the lowest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

United Therapeut ranks lowest with a EBITDA growth of -31.1%. Following is Gilead Sciences with a EBITDA growth of -27.5%. Amag Pharmaceuti ranks third lowest with a EBITDA growth of -13.8%.

Amgen Inc follows with a EBITDA growth of 5.8%, and Emergent Biosolu rounds out the bottom five with a EBITDA growth of 10.0%.

SmarTrend recommended that subscribers consider buying shares of Gilead Sciences on June 22nd, 2017 as our technology indicated a new Uptrend was in progress when shares hit $69.87. Since that recommendation, shares of Gilead Sciences have risen 3.6%. We continue to monitor Gilead Sciences for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest ebitda growth united therapeut Gilead Sciences amag pharmaceuti amgen inc emergent biosolu

Ticker(s): UTHR GILD AMAG AMGN EBS